Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other gastric mucus-associated proteins refers to a heterogeneous group of proteins and peptides, excluding the primary structural mucins (MUC5AC and MUC6), that constitute the gastric mucosal barrier [1]. This group includes the Trefoil Factor Family (TFF1, TFF2, TFF3), which are critical for epithelial restitution and repair, as well as antimicrobial proteins like lysozyme, lactoferrin, and various immunoglobulins (e.g., IgA) [2][3]. These proteins are essential for protecting the stomach lining from the corrosive effects of hydrochloric acid and pepsin [1]. They play a significant role in the innate immune response, particularly in the context of Helicobacter pylori infection [4]. In disease states such as gastric cancer or peptic ulcers, the expression profiles of these proteins are often significantly altered, making them potential biomarkers for disease progression [5]. While the group as a whole is not a single drug target, specific components like TFFs are investigated for their therapeutic potential in wound healing, and cytoprotective drugs like rebamipide act by stimulating the secretion of these protective factors [6]. [1] Allen A, Flemström G. (2005). Gastroduodenal mucus bicarbonate barrier: protection against acid and pepsin. Am J Physiol Cell Physiol. [2] Hoffmann W. (2015). Trefoil factor family (TFF) peptides and their link to inflammation and cancer. Curr Pharm Des. [3] Pelaseyed T, et al. (2014). The mucus and mucins of the goblet cells and enterocytes provide the first line of host defense and participate in oral tolerance. Immunol Rev. [4] Nardone G, et al. (2004). Effect of Helicobacter pylori infection on the expression of gastric mucosal trefoil peptides. Gut. [5] Newton JL, et al. (2000). The trefoil peptide TFF2 is reduced in Helicobacter pylori-associated gastritis. Gut. [6] Arakawa T, et al. (1998). Rebamipide: a novel gastroduodenal mucosal protective agent. Dig Dis Sci.
Stimulation of mucus secretion and enhancement of the mucosal barrier integrity
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other gastric mucus-associated proteins.